The earnings call conveyed a mostly positive outlook for Coherus Oncology, emphasizing strong revenue growth and strategic repositioning success. However, challenges with community adoption and dependency on future data readouts were noted.

Company Guidance -

Q3 2025

During the Coherus Oncology earnings call for Q2 2025, the company provided guidance on several key metrics reflecting its strategic progress and financial health. Coherus reported net revenue of $10 million for LOQTORZI, marking a 36% increase over Q1 2025 and a 65% increase year-over-year. The company aims to reach a revenue target of $40 million to $50 million for 2025, driven by growing adoption in the nasopharyngeal cancer market, estimated at $150 million to $200 million. Coherus also highlighted the potential of its pipeline assets, CHS-114 and casdozokitug, with promising clinical data expected by the first half of 2026. Financially, Coherus ended Q2 with $238 million in cash and investments, projecting sufficient funds to support operations through 2026. The company achieved approximately $30 million in annualized savings from headcount reductions and expects further savings as it continues to streamline operations.

Record Growth for LOQTORZI

LOQTORZI's net revenue in Q2 2025 grew 36% over Q1 2025 to $10 million, marking a 65% increase year-over-year. This growth was driven by strong demand and increased adoption by physicians.

Strategic Repositioning Completed

The company has been renamed to Coherus Oncology to focus on innovative oncology, completing a strategic repositioning.

Strong Financial Position

Ended Q2 with $238 million in cash and investments, providing a runway through 2026.

Cost Management Success

Achieved $30 million in annualized savings from headcount reductions, exceeding the $25 million target. SG&A costs are projected between $90 million and $100 million for 2025.

Coherus Biosciences (CHRS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CHRS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-0.33 / -	-0.09	―	―	―
Aug 07, 2025	2025 (Q2)	-0.22 / -0.39	-0.11	-254.55% (-0.28)	―
May 12, 2025	2025 (Q1)	-0.30 / -0.41	0.83	-149.40% (-1.24)	―
Mar 10, 2025	2024 (Q4)	-0.31 / -0.44	-0.71	38.03% (+0.27)	―
Nov 06, 2024	2024 (Q3)	-0.16 / -0.09	-0.41	78.05% (+0.32)	―
Aug 08, 2024	2024 (Q2)	-0.25 / -0.11	-0.49	77.55% (+0.38)	―
May 09, 2024	2024 (Q1)	-0.25 / 0.83	-0.96	186.46% (+1.79)	―
Mar 13, 2024	2023 (Q4)	-0.20 / -0.71	-0.76	6.58% (+0.05)	―
Nov 06, 2023	2023 (Q3)	-0.39 / -0.41	-1.11	63.06% (+0.70)	―
Aug 02, 2023	2023 (Q2)	-0.63 / -0.49	-0.65	24.62% (+0.16)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CHRS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$0.88	$0.82	-6.82%
May 12, 2025	$1.02	$0.82	-19.61%
Mar 10, 2025	$1.04	$1.05	+0.96%
Nov 06, 2024	$0.72	$0.82	+13.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Coherus Biosciences (CHRS) report earnings?

Coherus Biosciences (CHRS) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Coherus Biosciences (CHRS) earnings time?

Coherus Biosciences (CHRS) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CHRS EPS forecast?

CHRS EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing